ICIs work by unblocking the inhibitory signaling effect of immunomodulatory receptors expressed by immune or cancer cells (such as CTLA‐4 and PD‐1 or PD‐L1), which usually allow cancer cells to escape destruction. Here, PDCD1 is linked to cancer.